Table 3.
Comparison of pattern of drug resistance with previously available data.
| Drugs | National surveillance data 4 (691 patients), % | Mohan et al 3 (111 patients), n (%) | This study (43 patients), n (%) |
|---|---|---|---|
| INH | 49.05 | 103 (92.79) | 32 (74.4) |
| RIF | 12.59 | 91 (81.98) | 20 (46.5) |
| PZN | 30.82 | 52 (46.84) | 13 (30.23) |
| ETB | 10.13 | 57 (51.35) | 17 (39.53) |
| Amikacin | 4.34 | 5 (4.5) | 4 (9.30) |
| Kanamycin | 4.48 | 5 (4.5) | 3 (6.97) |
| Capreomycin | 4.63 | 1 (0.9) | 3 (6.97) |
| Ofloxacin | 16.4 | 36 (32.4) | 6 (13.95) |
| Moxifloxacin | 10.28 | 14 (12.6) | 7 (16.27) |
| Moxifloxacin (double dose) | NA | NA | 2 (4.65) |
| Clofazamine | NA | 0 | 2 (4.65) |
| Linezolid | NA | NA | 1 (2.32) |
| Ethionamide | 11.4 | 39 (35.1) | 3 (6.81) |
| PAS | 10.27 | 8 (7.2) | 4 (9.09) |
Abbreviations: INH, isoniazid; RIF, rifampicin; PZN, pyrazinamide; ETB, ethambutol; PAS, para-amino salicylic acid; NA, not applicable.